The Spanish Medicines Agency on Wednesday approved the start of clinical trials in humans of Spain’s first vaccine against the coronavirus.
“The Spanish Medicines and Health Products Agency (AEMPS) has authorized clinical trials of the PHH-1V vaccine against COVID-19 from the (Spanish) company Hipra,” AEPMS announced in a statement.
“This is the first human trial of a vaccine developed in Spain,” he said.
Spain’s Prime Minister Pedro Sánchez immediately hailed “a big step in the fight against the pandemic” on Twitter.
Today we are taking a big step in the fight against the pandemic. NS @AEMPSGOB has authorized the first human clinical trial of a Spanish vaccine against #COVID-19. This is the HIPRA vaccine, which has also got the support of the government to take the project forward. pic.twitter.com/UFBb1FErFj
— Pedro Sanchez (@sanchezcastejon) 11 August 2021
Each volunteer participating in the trial will be given two doses at 21-day intervals. According to Hipra, this vaccine will remain between 2 and 8 degrees Celsius, which will facilitate its distribution.
Hipra, headquartered in Amer, Catalonia, estimates that it could manufacture 400 million doses in 2022 and 1.2 billion in 2023 if the vaccine is approved for use.
It is based on recombinant protein, a formula used by the American company Novavax and a partnership between French laboratory Sanofi and the British GSK.
Internet geek. Wannabe bacon enthusiast. Web trailblazer. Music maven. Entrepreneur. Pop culture fan.
